• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Spero Therapeutics Announces Proposed Offering of Common Stock firstwordpharma
    July 10, 2018
    Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections
  • Spero Therapeutics Receives Grant from NIH americanpharmaceuticalreview
    May 05, 2017
    Spero Therapeutics announced it has received a grant from the National Institutes of Health (NIH) to conduct additional preclinical studies of SPR720, the company's novel oral bacterial gyrase inhibitor, for the treatment of tuberculosis (TB).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service